🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Evercore ISI cuts Albemarle target to $170 amid lithium price woes

EditorAhmed Abdulazez Abdulkadir
Published 28-08-2024, 05:06 pm
ALB
-

On Wednesday, Evercore ISI adjusted its financial outlook for Albemarle Corporation (NYSE:ALB), a global developer of lithium and other chemical solutions. The firm reduced the stock's price target to $170 from $190 while maintaining an Outperform rating. The reassessment comes as lithium chemical prices continue to decline, with index prices falling an additional 15-20% since mid-year, raising concerns about the producers' ability to weather a prolonged downturn.

Albemarle has already taken significant measures in response to the challenging market conditions. In the second quarter, the company reduced its capital expenditures and announced an impending write-down of approximately $1 billion on its Australian conversion projects, expected in the second half of the year.

Despite these challenges, Albemarle managed to secure a $2.3 billion capital raise through a mandatory convertible preferred offering in the first quarter and obtained some covenant relief on its net debt to EBITDA ratio.

The firm's analysis suggests that under the current price assumption of $12 per kilogram of lithium through 2026, Albemarle should be able to maintain its net debt to EBITDA ratio below the 3.5x threshold set by its credit agreement.

However, there is market concern that, with flat EBITDA of around $1.0 billion—a scenario that assumes steady earnings without considering potential cost or capital expenditure improvements—Albemarle's cash burn could push this ratio above 4x by 2025, exceeding the credit agreement's limit.

Evercore ISI acknowledges these concerns but also points to positive factors that could mitigate the impact. The firm emphasizes the potential growth from Albemarle's production that has already been paid for, which is expected to increase by over 15% even without the Kemerton project.

Additionally, the company is likely to benefit from the absence of lagged spodumene feedstock cost headwinds starting in early 2024. The firm's scenarios take a more comprehensive set of assumptions into account, suggesting a more nuanced outlook for Albemarle's financial health.

In other recent news, Albemarle Corporation, a leading chemical company, maintained an Outperform rating by BMO Capital Markets despite a slight decrease in the estimated earnings for 2024. The firm's projections for 2025, though reduced, remain higher than the consensus, based on an expected rebound in lithium prices. Deutsche Bank (ETR:DBKGn), Piper Sandler, and RBC Capital also adjusted their outlooks on Albemarle, citing the challenging lithium market conditions.

Albemarle reported a 40% decline in net sales in Q2 2024, with revenues totaling $1.4 billion. In response, the company initiated a comprehensive review of its cost and operating structure. Albemarle's peer, Arcadium Lithium, is also reassessing its operations due to falling lithium prices and increased production costs.

RBC Capital maintains optimism about Albemarle's performance due to strategic initiatives, including an ongoing asset rationalization program and productivity improvements that are expected to bolster the company's financial health.

InvestingPro Insights

As Albemarle Corporation (NYSE:ALB) navigates the challenges presented by declining lithium prices and market volatility, insights from InvestingPro provide a deeper understanding of the company's financial health and future prospects. According to InvestingPro Tips, the company has demonstrated a commitment to shareholder returns, raising its dividend for 31 consecutive years. This could be a sign of management's confidence in the company's long-term stability. However, analysts have expressed caution, revising their earnings downwards for the upcoming period and anticipating a sales decline in the current year.

Key metrics from InvestingPro Data reveal a complex picture. Albemarle's market capitalization stands at $10.46 billion, yet the company is grappling with negative growth, as revenue has decreased by 22.82% over the last twelve months as of Q2 2024. The negative gross profit margin of -8.18% during the same period underscores the challenges faced by the company. Despite this, the dividend yield remains at 1.82%, which could be appealing to income-focused investors.

For readers looking to delve further into Albemarle's financial analysis, InvestingPro offers additional tips that could shed light on the company's performance and stock price movements, which have been notably volatile recently. To explore these insights, visit https://www.investing.com/pro/ALB for a comprehensive set of InvestingPro Tips, including more on the company's profitability forecasts and liquidity position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.